The patients had previously treated inoperable or postoperatively relapsed NSCLC and received activated DCs pulsed with either autologous tumor lysates or peptide antigens (WT1, MUC1, CEA) matched to their HLA-A type (48). The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.